18 December 2024NewsAmericasRajiv Nayar, President, HTD Biosystems | Chuck Sholtz, Vice President, Intellectual Property, Nutcracker Therapeutics | Benjamin Pelletier, Partner, Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 April 2026   After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.
Americas
30 March 2026   A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.
Americas
19 March 2026   Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.